Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

Cheng E. Chee, David P. Steensma, Wenting Wu, Curtis A. Hanson, Ayalew Tefferi

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome.

Original languageEnglish (US)
Pages (from-to)611-613
Number of pages3
JournalAmerican Journal of Hematology
Volume83
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Hemosiderosis
Refractory Anemia
Erythrocyte Transfusion
Myelodysplastic Syndromes
Ferritins
Retrospective Studies
Survival
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. / Chee, Cheng E.; Steensma, David P.; Wu, Wenting; Hanson, Curtis A.; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 83, No. 8, 08.2008, p. 611-613.

Research output: Contribution to journalArticle

@article{233bc32a9be14f10b9e9ab8ceed90cbf,
title = "Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts",
abstract = "In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in {"}good risk{"} myelodysplastic syndrome.",
author = "Chee, {Cheng E.} and Steensma, {David P.} and Wenting Wu and Hanson, {Curtis A.} and Ayalew Tefferi",
year = "2008",
month = "8",
doi = "10.1002/ajh.21192",
language = "English (US)",
volume = "83",
pages = "611--613",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

AU - Chee, Cheng E.

AU - Steensma, David P.

AU - Wu, Wenting

AU - Hanson, Curtis A.

AU - Tefferi, Ayalew

PY - 2008/8

Y1 - 2008/8

N2 - In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome.

AB - In a retrospective study of 126 adult patients with French-American- British-defined refractory anemia with ringed sideroblasts (RARS), staging by the International Prognostic Scoring System was highly predictive of survival outcome (P < 0.0001). In addition, red blood cell (RBC) transfusion requirement at diagnosis (P = 0.001), but not the number of RBC units transfused during the disease course (P = 0.17), was independently associated with inferior survival. There were no correlations between survival and serum ferritin level, measured either at diagnosis (median 567 ng/mL, range 16-3,475; P = 0.24) or during follow-up (median 1,108 ng/mL; range 238-43,500; P = 0.72). Similarly, there was no difference in survival when patients were stratified by serum ferritin levels of < or ≥ 1,000 ng/mL at diagnosis or peak serum ferritin levels of <1,000, 1,000-5,000, or >5,000 ng/mL during follow-up. The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome.

UR - http://www.scopus.com/inward/record.url?scp=49149112388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149112388&partnerID=8YFLogxK

U2 - 10.1002/ajh.21192

DO - 10.1002/ajh.21192

M3 - Article

VL - 83

SP - 611

EP - 613

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 8

ER -